CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
A legfontosabb adatok
- Ki végzi
- REGENXBIO Inc.
- Hol
- New Brunswick, Oakland, Philadelphia és Pittsburgh (Egyesült Államok)Mind a 4 helyszín megnézéseMég 1 másik országban, 1 helyszínen
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 2/3. fázis
- Résztvevők
- 48 fő, tervezett
- Kezdés
- 2018. szept. 27.
- Befejezés
- 2025. aug.
- A vizsgálat típusa
- Beavatkozással járó, 6 csoport
- A vizsgált kezelések
- RGX-121
- A regiszteradat frissítve
- 2025. január 28.
Ki vehet részt
- Életkor
- 4 hónap – 5 év
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Egyéb feltételek
- Part 1 Inclusion Criteria:
- The subject's legal guardian(s) is (are) willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
- Is a male ≥4 months to < 5 years of age on Day 1
- Must meet any of the following criteria:; Has a documented diagnosis of MPS II and a has a neurocognitive testing score ≤ 77 (Bayley or Kaufman), OR; Has a documented diagnosis of MPS II AND has a decline of ≥ 1 standard deviation on serial neurocognitive testing administered between 3 to 36 months apart (Bayley or Kaufman) OR; Has a relative clinically diagnosed with severe MPS II who has the same IDS mutation as the subject AND in the opinion of a geneticist has inherited a severe form of MPS II OR; Has documented mutation (s) in IDS that in the opinion of a geneticist is always known to result in a neuronopathic phenotype AND in the opinion of a clinician has a severe form of MPS II; Part 2 Inclusion Criteria:
- The subject's legal guardian(s) is (are) willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
- Is a male ≥4 months to < 5 years of age on Day 1
- Has a documented diagnosis of neuronopathic MPS II. Neuronopathic MPS II can be documented with any of the following methods:; Has a BSID-III Cognitive Composite score at or below -1 SD (85) from normative mean; Has two consecutive neurodevelopmental assessments that support a decline on MSEL visual receptive, expressive language, or fine motor, or BSID-III cognition, expressive language, or fine motor ≥ 1 SD on serial neurocognitive testing administered between 3 to 36 months apart; Has a relative clinically diagnosed with neuronopathic MPS II who has the same IDS mutation as the subject AND the subject, in the opinion of a geneticist, has inherited a neuronopathic form of MPS II; Has documented mutation(s) in IDS known to result in a neuronopathic phenotype; Part 1 Exclusion Criteria:
- Has contraindications for intracisternal (IC) injection, intracerebroventricular (ICV) injection or lumbar puncture
- Has contraindications for immunosuppressive therapy
- Has neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
- Has a (cerebral) ventricular shunt that may impact the proper dosing of the subject
- Received hematopoietic stem cell transplantation
- Has had prior treatment with an AAV-based gene therapy product
- Received ELAPRASE® via intrathecal (IT) administration within 4 months of signing the ICF or experienced a serious hypersensitivity reaction to ELAPRASE®
- Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing the ICF, whichever is longer; Part 2 Exclusion Criteria:
- Has a contraindication for an IC injection, ICV injection or lumbar puncture
- Has contraindications for immunosuppressive therapy
- Has neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
- Has a (cerebral) ventricular shunt that may impact the proper dosing of the subject
- Received hematopoietic stem cell transplantation
- Has had prior treatment with an AAV-based gene therapy product
- Is receiving idursulfase (ELAPRASE®) via intrathecal (IT) administration, or a blood brain barrier-crossing enzyme replacement therapy. Subjects receiving IT ELAPRASE® or a blood brain barrier-crossing ERT may enroll if they agree to discontinue these therapies starting at least 3 months prior to dosing with RGX-121, and for the 24 months of follow-up
- Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing the ICF, whichever is longer
Helyszínek itt: Egyesült Államok
Még 1 másik országban, 1 helyszínen
- St. Peter's University HospitalNew Brunswick, Egyesült Államok
- University of California San Francisco, Benioff Children's HospitalOakland, Egyesült Államok
- Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
- Children's Hospital of Pittsburgh - UPMC: Program for Neurodevelopment in Rare DisordersPittsburgh, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety and efficacy, dose ranging study to determine whether RGX-121 is safe, effective and well-tolerated by patients with MPS II.
A vizsgálat 6 csoportja
- Part 1: RGX-121 Dose 1A vizsgált kezelés
1.3x10\^10 GC/g brain mass of RGX-121
Kezelés: RGX-121
- Part 1: RGX-121 Dose 2A vizsgált kezelés
6.5x10\^10 GC/g brain mass of RGX-121
Kezelés: RGX-121
- Part 1: RGX-121 Dose 2 Expanded CohortA vizsgált kezelés
6.5x10\^10 GC/g brain mass of RGX-121
Kezelés: RGX-121
- Part 1: RGX-121 Dose 3A vizsgált kezelés
2.0x10\^11 GC/g brain mass of RGX-121
Kezelés: RGX-121
- Part 1: RGX-121 Dose 3 Expanded CohortA vizsgált kezelés
2.9x10\^11 GC/g brain mass of RGX-121 (transgene-specific PCR assay) equivalent to, 2.0x10\^11 GC/g brain mass of RGX-121 (Poly-A-specific PCR assay)
Kezelés: RGX-121
- Part 2: RGX-121 Pivotal ExpansionA vizsgált kezelés
2.9x10\^11 GC/g brain mass of RGX-121 (transgene-specific PCR assay)
Kezelés: RGX-121
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)
- A regiszteradat frissítve
- 2025. január 28.